MP36-08 RISK FACTORS ASSOCIATED WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM COMPLICATIONS AMONG MEN WITH PEYRONIE’S DISEASE

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP36-08 RISK FACTORS ASSOCIATED WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM COMPLICATIONS AMONG MEN WITH PEYRONIE’S DISEASE Taher Naeem, Gal Saffati, Spoorthi Kamepalli, Sagar Patel, Basil Kaaki, Larry I. Lipshultz, and Mohit Khera Taher NaeemTaher Naeem More articles by this author , Gal SaffatiGal Saffati More articles by this author , Spoorthi KamepalliSpoorthi Kamepalli More articles by this author , Sagar PatelSagar Patel More articles by this author , Basil KaakiBasil Kaaki More articles by this author , Larry I. LipshultzLarry I. Lipshultz More articles by this author , and Mohit KheraMohit Khera More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003270.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: In the United States, collagenase clostridium histolyticum (CCH) injections are widely used as a treatment for patients with Peyronie’s disease (PD). Although some studies have examined adverse events associated with CCH injections, none have studied their relationship to peri-procedural patient characteristics. The objective of this study is to evaluate peri-procedural risk factors associated with various known CCH complications for PD. METHODS: We performed an IRB-approved single-center retrospective study from 2009-2022 on patients with CCH injections for PD. Clinical and demographic information was extracted from patient medical records. Multivariate logistic regression modeling was used to identify statistically significant (p<0.05) associations between peri-procedural factors and injection complications. RESULTS: We identified 282 PD patients who received CCH injections. Of these patients, 33.3% (n=94) experienced bruising, 10.6% (n=30) experienced swelling, 24.8% (n=70) experienced pain, 7.4% (n=21) experienced a hematoma, and 2.1% (n=6) experienced a penile fracture (PF). We found that patients with erectile dysfunction (ED) were 3 times (Odds Ratio [OR]: 0.3, 95% Confidence Interval [CI]: 0.1-0.9) less likely to experience bruising following CCH injection as patients without ED. Additionally, patients on anticoagulants were 17 times (OR: 17, CI: 2.2-144) more likely to develop a hematoma following CCH treatment, although being on anticoagulants was not significantly associated with bruising as an adverse effect. CONCLUSIONS: We found that most CCH complications were low-grade in nature, with rare occurrences of more severe complications such as PF. We also found that having ED and being on anti-coagulants were associated with more significant complications following CCH treatment in patients with PD. These findings highlight the overall safety of CCH injections for treatment of PD and may inform clinical decisions for patients with certain risk factors. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e481 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Taher Naeem More articles by this author Gal Saffati More articles by this author Spoorthi Kamepalli More articles by this author Sagar Patel More articles by this author Basil Kaaki More articles by this author Larry I. Lipshultz More articles by this author Mohit Khera More articles by this author Expand All Advertisement PDF downloadLoading ...